Compare NGVC & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGVC | CTMX |
|---|---|---|
| Founded | 1955 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.8M | 642.2M |
| IPO Year | 2012 | 2015 |
| Metric | NGVC | CTMX |
|---|---|---|
| Price | $31.62 | $3.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $36.00 | $12.10 |
| AVG Volume (30 Days) | 95.7K | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | ★ 36.05 | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $7.08 | N/A |
| Revenue Next Year | $6.04 | $7.61 |
| P/E Ratio | $29.58 | ★ $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.47 | $1.72 |
| 52 Week High | $45.98 | $8.21 |
| Indicator | NGVC | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 51.69 | 40.78 |
| Support Level | $30.36 | $2.82 |
| Resistance Level | $34.24 | $3.94 |
| Average True Range (ATR) | 1.21 | 0.19 |
| MACD | -0.32 | -0.05 |
| Stochastic Oscillator | 54.36 | 14.02 |
Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories: natural and organic food, dietary supplements, natural body care, household, pet care products, books, and handouts. The Company has a single reporting segment, natural and organic retail stores, through which business is conducted. The company generates the majority of its revenue from grocery products and dietary supplements, and the rest from other products.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.